RE:RE:RE:RE:RE:Phase 2/3 OV company Genelux trades at US$35.00Yes, Genelux is a competitor and an interesting comparison.
They are active in different indications than ONCY but parallels are striking.
Note they had an IPO six months ago at $6 US.
They have about 24 mil shares out.
We are a bit over $2 US and have 63 mil shares out.
The opportunity offered by Genelux at its IPO is comparable to the equity available in buying shares in ONCY at the current price.
The difference is they have started their P3 in ovarian.
We are expected to have two p3s going in the second half of this year.
Genelux is getting its overian trial enrolled at the BC Cancer Center among other sites.